Momenta Phama (MNTA) Lower; FDA Approves Generic Lovenox (TEVA)

Momenta Phama (NASDAQ: MNTA) is lower today after the FDA approved the generic version of Lovenox.

According to the FDA website, Teva's enoxaparin sodium was approved on June 23, 2014. More information about the drug can be found here.

Momenta is down 5.2 percent.

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• Milestone Pharmaceuticals starts Phase 3 AFib-RVR trial for etripamil
• Radiopharm trial advances to higher dose in HER2+ cancer study